secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALUMIS INC. (ALMS)
CIK:        0001847367
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001847367-26-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alumis reports 2025 net loss $243.3M; Phase 3 envudeucitinib meets endpoints; NDA plan 2H2026
--------------------------------------------------------------------------------

- Net loss of $243.3M vs. $294.2M in 2024; revenue $24.1M from Kaken license.
- Cash, cash equivalents and marketable securities $308.5M at Dec 31, 2025.
- Jan 2026 public offering raised $345.1M gross; net proceeds $324.4M extend runway into Q4 2027.
- R&D expenses $386.0M, up 45% YoY, driven by Phase 3 ONWARD program and merger costs.
- NDA for envudeucitinib in plaque psoriasis on track for 2H2026; SLE Phase 2b data expected 3Q2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/0001847367-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319x8k.htm
  HTML page:      https://secwatch.observer/filing/0001847367-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer